摘要:
A non-steroidal anti-inflammatory composition comprising an active anti-inflammatory agent having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen or lower alkyl C.sub.1-8. The active agent is formulated with a pharmaceutically acceptable carrier for use in the treatment of pain, inflammation and other related symptoms on mammals; preferably, R.sub.1 amd R.sub.2 are both methyl.
摘要翻译:一种非甾体抗炎组合物,其包含具有下式的活性抗炎剂:其中R 1和R 2是氢或低级烷基C 1-8。 活性剂与药学上可接受的载体配制,用于治疗哺乳动物的疼痛,炎症和其它相关症状; 优选地,R 1 amd R 2都是甲基。
摘要:
A non-steroidal anti-inflammatory composition comprising an active anti-inflammatory agent having the formula: ##STR1## The active agent is formulated with a pharmaceutically acceptable carrier for use in the treatment of pain, inflammation and other related symptoms on mammals.
摘要:
A method for improving the integrity of the corneal epithelium by introducing into the eye an effective amount of a ophthalmically compatible retinoid sufficient to enhance the integrity of the corneal epithelium.
摘要:
The invention provides a method for inhibiting the binding of a biguanide antimicrobial in aqueous solution to a hydrogel in contact with said solution comprising providing in said solution an amount of cyclodextrin sufficient to inhibit sorption of the biguanide antimicrobial to a hydrogel.
摘要:
A non-steroidal anti-inflammatory composition comprising an active anti-inflammatory agent having the formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 is hydrogen, hydroxy, phenyl, methoxy, carboxylic acid, sulfhydryl or hydroxamic acid.The active agent is formulated with a pharmaceutically acceptable carrier for use in the treatment of pain, inflammation and other related symptoms on mammals. p-Hydroxydiphenyl, p-methoxyphenol, thiosalicylic acid, benzyl alcohol and salicylhydroxamic acid are preferred.
摘要:
An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid. The composition has a viscosity in the range from about 300 cp to about 1500 cp, and a total concentration of cations of less than about 50 mM. The ophthalmic composition is used to treat patients suffering from allergic conjunctivitis, and includes instructing a person suffering from ocular itching resulting from allergic conjunctivitis to administer once or twice daily in the form of one or more eye drops the aqueous ophthalmic composition described.
摘要:
A process and composition for inhibiting surfactant irritation and insult comprising an aqueous solution of a surfactant and an effective amount of an irritation inhibitor selected from the group consisting of lecithin, sodium cetearyl sulfate, an amino acid, cocamine compounds, amine oxides, glyceryl monoesters, ethoxylated monocarboxylic acids, ethoxylated hydroxyl compounds and mixtures thereof.
摘要:
A non-steroidal anti-inflammatory composition comprising an active anti-inflammatory agent having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen hydroxy. The active agent is formulated with a pharmaceutically acceptable carrier for use in the treatment of pain, inflammation and other related symptoms on mammals. Benzyl paraben, benzyl salicylate and benzyl benzoate are preferred.
摘要:
An aqueous ophthalmic composition comprises a carboxy-containing polyanionic polymer that has a viscosity in the range from about 300 cp to about 1500 cp outside the eye and a total concentration of cations of less than about 50 mM, wherein the viscosity of the composition does not increase when the composition comes into contact with surface ocular fluid.
摘要:
The invention provides an ophthalmic aqueous composition for topical administration, comprising: (a) a block copolymer of propylene oxide and ethylene oxide in concentration sufficient to provide viscosity of less than about 25 centipoise at ambient temperature and viscosity of from about 25 to about 55 centipoise when applied topically to a patient; (b) hydroxypropyl methylcellulose in concentration sufficient to improve the durability of the gel formed by the block copolymer. The invention further provides a method for administering ophthalmic pharmaceuticals.